What is Stemedica Cell Technologies?
Stemedica Cell Technologies, Inc. is a clinical-stage biopharmaceutical firm focused on creating and commercializing progenitor cell and protein therapeutics for conditions with limited treatment options. Leveraging a proprietary platform, the company produces high-quality progenitor cells within a cGMP-licensed facility. Stemedica is actively engaged in clinical trials across the United States for severe medical conditions, including ischemic stroke and Alzheimer's disease. The company's strategic direction is guided by a seasoned team of scientists and management, aiming to tackle significant healthcare challenges with novel therapeutic solutions.
How much funding has Stemedica Cell Technologies raised?
Stemedica Cell Technologies has raised a total of $69.1M across 4 funding rounds:
Series A
$45M
Series B
$22M
Debt
$1M
Debt
$1.1M
Series A (2008): $45M, investors not publicly disclosed
Series B (2009): $22M, investors not publicly disclosed
Debt (2020): $1M supported by PPP
Debt (2021): $1.1M featuring PPP
Key Investors in Stemedica Cell Technologies
PPP
Public-Private Partnership
What's next for Stemedica Cell Technologies?
The recent major strategic investment signals a pivotal moment for Stemedica Cell Technologies, likely enabling the acceleration of its ongoing clinical trials for ischemic stroke and Alzheimer's disease. This capital infusion is expected to support the advancement of its proprietary progenitor cell and protein therapeutics through critical development phases, potentially paving the way for regulatory submissions and eventual commercialization. The company's focus on underserved medical conditions positions it for significant growth and impact within the biopharmaceutical sector.
See full Stemedica Cell Technologies company page
